Welcome to our dedicated page for Enlivex Ltd. SEC filings (Ticker: ENLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enlivex Ltd.’s SEC filings document its status as an Israeli foreign private issuer with ordinary shares listed under ENLV, its clinical-stage Allocetra™ program, and its prediction markets treasury strategy centered on the RAIN token and Rain protocol.
Recent Form 6-K reports furnish current disclosures on regulatory clearances for Allocetra™ in age-related knee osteoarthritis, annual financial results, tokenized representations of the company’s ordinary shares, Rain protocol ecosystem updates, senior secured convertible debt, and the completed corporate name change from Enlivex Therapeutics Ltd. to Enlivex Ltd. The filings also reference registration statements and governance records tied to shareholder approvals and capital structure.
Enlivex Ltd. reports that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra™, its clinical-stage immunotherapy, for treating age-related symptomatic knee osteoarthritis in patients aged 64 and older. RMAT status is based on a completed Phase I/IIa trial in which Allocetra™ showed statistically significant and clinically meaningful improvements in knee pain and physical function versus placebo, with durability of response through at least six months. Enlivex has started a randomized, controlled Phase IIb trial in the United States and European Union, planning to enroll 182 primary knee osteoarthritis patients aged 64 and older, and expects top-line data by the end of the second quarter of 2027. In connection with the designation, the FDA has requested a Type B meeting to discuss the Allocetra™ development program. Enlivex also describes itself as a quality longevity company that combines development of Allocetra™ with a prediction markets treasury strategy built around the Rain Protocol.
Enlivex Ltd. is implementing a 1-for-15 reverse split of its ordinary shares, effective when trading begins on a split-adjusted basis on July 9, 2026 on the Nasdaq Capital Market under the symbol ENLV.
Every 15 ordinary shares will be combined into one, reducing authorized ordinary shares from 2,375,000,000 to 158,333,334 and increasing par value per share from NIS 0.40 to NIS 6.00. Issued and outstanding ordinary shares will decrease from 252,480,222 to approximately 16,832,015, with fractional shares rounded up to the nearest whole share. Ownership percentages and voting rights remain essentially unchanged, aside from minor rounding effects.
The company describes itself as a quality longevity business developing its Allocetra™ immunotherapy for age-related inflammatory conditions, alongside a prediction markets treasury strategy built around the Rain Protocol on Arbitrum.
Enlivex Ltd. reported that its primary treasury asset, the RAIN token, is expected to begin trading on the Gate cryptocurrency exchange on June 24, 2026 at 10:00 AM UTC. Gate is described as one of the world’s largest digital asset platforms by spot trading volume and liquidity.
Enlivex highlighted that the Gate listing expands RAIN’s exchange infrastructure and is intended to increase accessibility, global reach, and token liquidity. The company’s digital asset treasury strategy is centered on acquiring RAIN tokens.
Enlivex previously disclosed that, as of June 21, 2026, it held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion, corresponding to a treasury NAV per share of $4.67. The company continues to advance its Allocetra immunotherapy programs while maintaining this prediction-markets-focused treasury approach.
Enlivex Ltd. reported an update on its digital asset treasury, focusing on its RAIN token position. As of June 20, 2026, the company held 79,568,550,005 RAIN tokens, with an approximate mark-to-market value of $1.14 billion. Based on these holdings relative to its ordinary shares outstanding, Enlivex reported an unaudited Treasury NAV per Share of $4.67 as of the same date. Updated treasury metrics are available on the company’s public dashboard, while broader token trading data is accessible via a third‑party crypto data site. Enlivex reiterates that its business combines clinical-stage longevity therapeutics (Allocetra™) with a prediction markets‑driven treasury strategy centered on the Rain protocol and highlights extensive risks and uncertainties around digital assets, regulation, market conditions, and RAIN price and liquidity.
Enlivex Ltd. reported an updated position in its digital asset treasury, stating that as of May 27, 2026 it held 79,568,550,005 RAIN tokens valued at approximately $1.16 billion. Management frames RAIN as a core treasury asset alongside its longevity-focused Allocetra™ immunotherapy programs.
The Rain Foundation, which oversees the Rain protocol used in Enlivex’s prediction markets strategy, has appointed five well-known crypto and blockchain figures to its advisory board and committed $100 million of liquidity to the protocol. The Foundation reports more than 29,000 users and over 100 million RAIN tokens burned via its buyback-and-burn mechanism, positioning Rain as the third-largest prediction market protocol globally by Total Value Locked compared with about $450 million for category leader Polymarket.
Enlivex Ltd. reported that the Rain Foundation has committed $100 million in additional liquidity to the Rain prediction markets protocol, split between $50 million in USDT and $50 million in RAIN tokens. This liquidity currently makes Rain the third-largest prediction market protocol globally by Total Value Locked, alongside Polymarket, which has about $450 million in TVL.
Enlivex’s Executive Chairman described Rain’s new ranking as an important milestone for Rain and a validation of Enlivex’s prediction markets–focused treasury strategy. Enlivex currently holds approximately 79,568,550,005 RAIN tokens and expects the continued development of prediction markets to support the strategic value of these holdings, alongside its clinical-stage Allocetra™ immunotherapy programs.
Enlivex Ltd. reports dosing the first patient at a United States clinical site in its global Phase 2b trial of Allocetra™ for moderate-to-severe age-related primary knee osteoarthritis. This marks the start of U.S. enrollment in a randomized, double-blind, placebo-controlled study.
The multicenter trial spans sites in the United States, Denmark and Poland and evaluates intra-articular Allocetra™ injections. Key efficacy measures track pain and physical function at three and six months, with additional quality-of-life and mobility endpoints. Enlivex positions Allocetra™ within a broader strategy that combines longevity-focused immunotherapy development with a prediction markets treasury built around the Rain protocol.
Enlivex Ltd. reports it has received a Nasdaq notice that its ordinary shares failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days, until November 9, 2026, to regain compliance by having a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. If it meets other listing standards, Enlivex may qualify for an additional 180‑day period, after which its shares could face delisting if compliance is not restored. The notice does not immediately affect the listing or trading of Enlivex’s shares or its business operations.
Enlivex Ltd. registers 23,333,333 ordinary shares for resale by a selling shareholder pursuant to a senior secured convertible promissory note. The shares are issuable under the Note and represent the company’s good-faith estimate of the maximum Note Conversion Shares. The company will receive no proceeds from resales; net proceeds go to the selling shareholder.